The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions
Abstract
Placebo‐associated improvements have been previously documented in small series of Parkinson's disease (PD) patients. Using a strict definition of placebo‐associated improvement, we examined rates and timing of placebo responses to identify patient‐ and study‐based characteristics, predicting positive placebo response in several PD clinical trials. We collected individual patient data from the placebo groups of 11 medical and surgical treatment trials involving PD patients with differing PD severities and placebo‐assignment likelihoods. We defined a positive placebo response as ≥50% improvement in total Unified Parkinson's Disease Rating Scale motor (UPDRSm) score or a decrease by ≥2 points on at least two UPDRSm items compared to baseline. We calculated positive placebo response rates at early (3–7 weeks), mid (8–18 weeks), and late (23–35 weeks) stages of follow‐up. Odds ratios for patient‐ and study‐based characteristics were obtained from a model fitted using generalized estimating equations. There were 858 patients on placebo who met inclusion criteria for analysis. Three studies involved patients without need of symptomatic treatment, two involved patients without motor fluctuations needing symptomatic treatment, and six (three medical and three surgical) involved patients with motor fluctuations. The overall placebo response rate was 16% (range: 0–55%). Patients with higher baseline UPDRSm scores and studies that focused on PD with motor fluctuations, surgical interventions, or those with a higher probability of placebo assignment showed increased odds of positive placebo response. Placebo responses were temporally distributed similarly during early, mid, and late phases of follow‐up. Placebo‐related improvements occur in most PD clinical trials and are similarly distributed across all 6 months of follow‐up. Recognition of factors that impact placebo response rates should be incorporated into individual study designs for PD clinical trials. © 2008 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Rat Brain in Stereotaxic Coordinates
(1982) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 51,963
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K.-Y. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,764
Predictive reward signal of dopamine neurons
Schultz, W. (1998) · Journal of Neurophysiology · doi:10.1152/jn.1998.80.1.1 · Cited by 4,564
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Self-citationPlacebo-Induced Changes in fMRI in the Anticipation and Experience of Pain
Wager, T. D., Rilling, J. K., Smith, E. E., Sokolik, A., Casey, K. L., Davidson, R. J., Kosslyn, S. M., Rose, R. M., & Cohen, J. D. (2004) · Science · doi:10.1126/science.1093065 · Cited by 1,992
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2003) · Movement Disorders · doi:10.1002/mds.10473 · Cited by 1,810
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Is the Placebo Powerless?: An Analysis of Clinical Trials Comparing Placebo with No Treatment
Hróbjartsson, A., & Gøtzsche, P. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442106 · Cited by 1,503
Placebo and Opioid Analgesia-- Imaging a Shared Neuronal Network
Petrovic, P., Kalso, E., Petersson, K. M., & Ingvar, M. (2002) · Science · doi:10.1126/science.1067176 · Cited by 1,488
Ikemoto, S., & Panksepp, J. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00023-5 · Cited by 1,450
Goetz, C. G., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stebbins, G. T., Stern, M. B., Tilley, B. C., Dodel, R., Dubois, B., et al. (2007) · Movement Disorders · doi:10.1002/mds.21198 · Cited by 1,404
Self-citationA double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
Olanow, C. W., Goetz, C. G., Kordower, J. H., Stoessl, A. J., Sossi, V., Brin, M. F., Shannon, K. M., Nauert, G. M., Perl, D. P., Godbold, J., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10720 · Cited by 1,307
Self-citationEffects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Core assessment program for intracerebral transplantations (CAPIT)
Langston, J. W., Widner, H., Goetz, C. G., Brooks, D., Fahn, S., Freeman, T., & Watts, R. (1992) · Movement Disorders · doi:10.1002/mds.870070103 · Cited by 1,008
Self-citationTRANSPLANTATION OF EMBRYONIC DOPAMINE NEURONS FOR SEVERE PARKINSON'S DISEASE
Reed, R., Reene, P. A. E. G., Reeze, R. O. E. B., Ei, W., Ouchel, W. I. D. U. M., Ao, R. I. K., Infield, W., Ulver, S. H. C., Rojanowski, J. O. Q. T., Idelberg, D. A. E., et al. (2001) · Cited by 1,001
Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease
de la Fuente-Fernández, R., Ruth, T. J., Sossi, V., Schulzer, M., Calne, D. B., & Stoessl, A. J. (2001) · Science · doi:10.1126/science.1060937 · Cited by 991
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Patient compliance with paper and electronic diaries
Stone, A. A., Shiffman, S., Schwartz, J. E., Broderick, J. E., & Hufford, M. R. (2003) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00320-3 · Cited by 910
Neurobiological Mechanisms of the Placebo Effect
Benedetti, F., Mayberg, H. S., Wager, T. D., Stohler, C. S., & Zubieta, J.-K. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3458-05.2005 · Cited by 777
The Functional Neuroanatomy of the Placebo Effect
Mayberg, H. S., Silva, J. A., Brannan, S. K., Tekell, J. L., Mahurin, R. K., McGinnis, S., & Jerabek, P. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.728 · Cited by 720
A Controlled Trial of Rasagiline in Early Parkinson Disease: The TEMPO Study
(2002) · Archives of Neurology · doi:10.1001/archneur.59.12.1937 · Cited by 579
Overt versus covert treatment for pain, anxiety, and Parkinson's disease
Colloca, L., Lopiano, L., Lanotte, M., & Benedetti, F. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00908-1 · Cited by 552
The NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
(2005) · Archives of Neurology · doi:10.1001/archneur.62.2.241 · Cited by 418
Noseworthy, J. H., Ebers, G. C., Vandervoort, M. K., Farquhar, R. E., Yetisir, E., & Roberts, R. (1994) · Neurology · doi:10.1212/wnl.44.1.16 · Cited by 341
Benedetti, F., Colloca, L., Torre, E., Lanotte, M., Melcarne, A., Pesare, M., Bergamasco, B., & Lopiano, L. (2004) · Nature Neuroscience · doi:10.1038/nn1250 · Cited by 309
Entacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patients
(1997) · Annals of Neurology · doi:10.1002/ana.410420511 · Cited by 308
Ropinirole for the treatment of early Parkinson's disease
Adler, C. H., Sethi, K. D., Hauser, R. A., Davis, T. L., Hammerstad, J. P., Bertoni, J., Taylor, R. L., Sanchez-Ramos, J., O'Brien, C. F., & Ropinirole Study Group (1997) · Neurology · doi:10.1212/wnl.49.2.393 · Cited by 281
Self-citationMcRae, C., Cherin, E., Yamazaki, T. G., Diem, G., Vo, A. H., Russell, D., Ellgring, J. H., Fahn, S., Greene, P., Dillon, S., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.4.412 · Cited by 278
Self-citationStocchi, F., Vacca, L., Ruggieri, S., & Olanow, C. W. (2005) · Archives of Neurology · doi:10.1001/archneur.62.6.905 · Cited by 229
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease
Lieberman, A., Olanow, C. W., Sethi, K., Swanson, P., Waters, C. H., Fahn, S., Hurtig, H., Yahr, M., & the Ropinirole Study Group* (1998) · Neurology · doi:10.1212/wnl.51.4.1057 · Cited by 223
Self-citationFactor structure of the unified Parkinson's disease rating scale: Motor examination section
Stebbins, G. T., & Goetz, C. G. (1998) · Movement Disorders · doi:10.1002/mds.870130404 · Cited by 201
Self-citationThe placebo effect in neurological disorders
de la Fuente-Fernández, R., Schulzer, M., & Stoessl, A. J. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00038-8 · Cited by 187
Levodopa therapy: Consequences of the nonphysiologic replacement of dopamine
Chase, T. N. (1998) · Neurology · doi:10.1212/wnl.50.5_suppl_5.s17 · Cited by 180
The Significance of Continuous Dopaminergic Stimulation in the Treatment of Parkinson??s Disease
Chase, T. N. (1998) · Drugs · doi:10.2165/00003495-199855001-00001 · Cited by 167
Objective changes in motor function during placebo treatment in PD
Goetz, C. G., Leurgans, S., Raman, R., & Stebbins, G. T. (2000) · Neurology · doi:10.1212/wnl.54.3.710 · Cited by 162
Self-citationMercado, R., Constantoyannis, C., Mandat, T. S., Kumar, A., Schulzer, M., Stoessl, A. J., & Honey, C. R. (2006) · Movement Disorders · doi:10.1002/mds.20935 · Cited by 137
Goetz, C. G., Leurgans, S. E., & Raman, R. (2002) · Movement Disorders · doi:10.1002/mds.10024 · Cited by 135
Self-citationPlacebo influences on dyskinesia in Parkinson's disease
Goetz, C. G., LASKA, E. M., Hicking, C., Damier, P., Müller, T. H., Nutt, J. G., Olanow, C. W., Rascol, O., & Russ, H. (2008) · Movement Disorders · doi:10.1002/mds.21897 · Cited by 131
Self-citationClinical–Pathological study of levodopa complications
Rajput, A. H., Fenton, M. E., Birdi, S., Macaulay, R. J. B., George, D. H., Rozdilsky, B., Ang, L. C., Senthilselvan, A., & Hornykiewicz, O. (2002) · Movement Disorders · doi:10.1002/mds.10031 · Cited by 127
Smith, L. A., Jackson, M. J., Al‐Barghouthy, G., Rose, S., Kuoppamäki, M., Olanow, C. W., & Jenner, P. G. (2005) · Movement Disorders · doi:10.1002/mds.20421 · Cited by 112
Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?
Nutt, J. G. (2006) · Movement Disorders · doi:10.1002/mds.21060 · Cited by 109
Continuous dopaminergic stimulation in early and advanced Parkinson’s disease
Stocchi, F., & Olanow, C. W. (2004) · Neurology · doi:10.1212/wnl.62.1_suppl_1.s56 · Cited by 87
Science and Ethics of Sham Surgery
Kim, S. Y. H., Frank, S., Holloway, R. G., Zimmerman, C. F., Wilson, R. M., & Kieburtz, K. D. (2005) · Archives of Neurology · doi:10.1001/archneur.62.9.1357 · Cited by 75
Uncovering the hidden placebo effect in deep-brain stimulation for Parkinson's disease
de la Fuente‐Fernández, R. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2003.10.003 · Cited by 67
SCIENTIFIC AND ETHICAL ISSUES IN THE USE OF PLACEBO CONTROLS IN CLINICAL TRIALS
Clark, P. I., & Leaverton, P. E. (1994) · Annual Review of Public Health · doi:10.1146/annurev.pu.15.050194.000315 · Cited by 66
The Biochemical Bases for Reward: Implications for the Placebo Effect
de la Fuente‐Fernández, R., & Stoessl, A. J. (2002) · Evaluation & the Health Professions · doi:10.1177/0163278702238052 · Cited by 65
Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease
Arabia, G., Zappia, M., Bosco, D., et al. (2002) · Neurological Sciences · doi:10.1007/s100720200066 · Cited by 61
Coenzyme Q10 in Early Parkinson Disease
Hunter, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1170-a · Cited by 33
Striatal molecular mechanisms and motor dysfunction in Parkinson's disease.
Chase, T. N., Konitsiotis, S., & Oh, J. D. (2001) · PubMed · Cited by 23
Double-Blind, Placebo-Controlled Trials for Surgical Interventions in Parkinson Disease
Olanow, C. W. (2005) · Archives of Neurology · doi:10.1001/archneur.62.9.1343 · Cited by 19
Cited by
Lees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956
The neuroscience of placebo effects: connecting context, learning and health
Wager, T. D., & Atlas, L. Y. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3976 · Cited by 844
Missing pieces in the Parkinson's disease puzzle
Obeso, J. A., Rodriguez-Oroz, M. C., Goetz, C. G., Marin, C., Kordower, J. H., Rodriguez, M., Hirsch, E. C., Farrer, M., Schapira, A. H. V., & Halliday, G. (2010) · Nature Medicine · doi:10.1038/nm.2165 · Cited by 734
Self-citationWilliams, A., Gill, S., Varma, T., Jenkinson, C., Quinn, N., Mitchell, R., Scott, R., Ives, N., Rick, C., Daniels, J., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70093-4 · Cited by 733
Holtzheimer, P. E., Husain, M. M., Lisanby, S. H., Taylor, S. F., Whitworth, L. A., McClintock, S., Slavin, K. V., Berman, J., McKhann, G. M., Patil, P. G., et al. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30371-1 · Cited by 577
Metadata
- Authors
- Goetz, C. G., Wuu, J., McDermott, M. P., Adler, C. H., Fahn, S., Freed, C. R., Hauser, R. A., Olanow, W. C., Shoulson, I., Tandon, P. K., Parkinson Study Group, & Leurgans, S.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2008-01-28
- Volume
- 23
- Issue
- 5
- Pages
- 690-699
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2013110094
- Cited by
- 253
- References
- 52
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.